Pages with the most revisions

Jump to navigation Jump to search

Showing below up to 500 results in range #51 to #550.

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)

  1. Justification‏‎ (5 revisions)
  2. Computed tomography dose index‏‎ (4 revisions)
  3. Direct bioassay‏‎ (4 revisions - redirect page)
  4. Bioassay‏‎ (4 revisions)
  5. Calculating Radon Doses‏‎ (4 revisions)
  6. Alpha decay‏‎ (4 revisions)
  7. Kp index‏‎ (4 revisions)
  8. Effective charge number‏‎ (4 revisions)
  9. Protective action‏‎ (4 revisions)
  10. Reference Animal and Plant‏‎ (4 revisions)
  11. Source-related assessment‏‎ (4 revisions)
  12. Risk‏‎ (4 revisions)
  13. Senescence‏‎ (4 revisions)
  14. Effective half-life‏‎ (4 revisions)
  15. Averted dose‏‎ (4 revisions)
  16. Reference bioassay function‏‎ (4 revisions)
  17. Optimisation‏‎ (4 revisions)
  18. Forbiddenness‏‎ (4 revisions)
  19. Aerodynamic diameter‏‎ (4 revisions)
  20. ICRP‏‎ (4 revisions)
  21. Sievert‏‎ (4 revisions)
  22. Diagnostic reference level‏‎ (4 revisions)
  23. S coefficient (radiation weighted)‏‎ (4 revisions)
  24. Non-maleficence‏‎ (4 revisions)
  25. Air-kerma, product‏‎ (4 revisions)
  26. Fractionation sensitivity‏‎ (4 revisions)
  27. Mass median diameter‏‎ (4 revisions)
  28. Air kerma at the patient entrance reference point‏‎ (4 revisions)
  29. Math‏‎ (4 revisions)
  30. Programmed cell death‏‎ (4 revisions)
  31. High linear energy transfer radiation‏‎ (4 revisions)
  32. Target region‏‎ (3 revisions)
  33. Growth fraction‏‎ (3 revisions)
  34. Excretion rate (instantaneous)‏‎ (3 revisions)
  35. Extrathoracic airways‏‎ (3 revisions)
  36. Galactic cosmic radiation‏‎ (3 revisions)
  37. Growth hormone (somatotropin)‏‎ (3 revisions)
  38. ICRP Publication 103‏‎ (3 revisions)
  39. DNA damage signalling‏‎ (3 revisions)
  40. Potential exposure‏‎ (3 revisions)
  41. Fairness‏‎ (3 revisions)
  42. Absorption‏‎ (3 revisions)
  43. Gamma ray‏‎ (3 revisions)
  44. Cardiomyopathy‏‎ (3 revisions)
  45. Rigidity threshold‏‎ (3 revisions)
  46. Low Earth orbit‏‎ (3 revisions)
  47. Dose equivalent‏‎ (3 revisions)
  48. X ray‏‎ (3 revisions)
  49. Field-size effect (Volume effect)‏‎ (3 revisions)
  50. Gastrointestinal syndrome‏‎ (3 revisions)
  51. Biomedical research volunteer‏‎ (3 revisions)
  52. Dose limit‏‎ (3 revisions)
  53. Unsealed source‏‎ (3 revisions)
  54. Xerostomia‏‎ (3 revisions)
  55. Flexible tissues‏‎ (3 revisions)
  56. Guide to the System of Radiological Protection‏‎ (3 revisions)
  57. Autonomy‏‎ (3 revisions)
  58. Constancy test‏‎ (3 revisions)
  59. Interphase death‏‎ (3 revisions)
  60. Test‏‎ (3 revisions)
  61. Dose‏‎ (3 revisions)
  62. Dose limits‏‎ (3 revisions)
  63. Fluence‏‎ (3 revisions)
  64. Public exposure‏‎ (3 revisions)
  65. DS02‏‎ (3 revisions)
  66. Uptake‏‎ (3 revisions)
  67. Fluoroscopically guided interventions‏‎ (3 revisions)
  68. Annual dose‏‎ (3 revisions)
  69. Cell death‏‎ (3 revisions)
  70. Contamination‏‎ (3 revisions)
  71. Dose of record (E)‏‎ (3 revisions)
  72. Utilitarian ethics‏‎ (3 revisions)
  73. Operational quantity‏‎ (3 revisions)
  74. Accountability‏‎ (3 revisions)
  75. Half-life, physical‏‎ (3 revisions)
  76. Value judgement‏‎ (3 revisions)
  77. Exponential survival curve‏‎ (3 revisions)
  78. Annual limit on intake‏‎ (3 revisions)
  79. Dose per content function‏‎ (3 revisions)
  80. Valvular heart disease‏‎ (3 revisions)
  81. Equity‏‎ (3 revisions)
  82. Personal dose equivalent‏‎ (3 revisions)
  83. Principle of justification‏‎ (3 revisions)
  84. Graded approach‏‎ (3 revisions)
  85. Radiofrequency ablation‏‎ (3 revisions)
  86. Iso-effect plots‏‎ (3 revisions)
  87. Lifetime risk estimates‏‎ (3 revisions)
  88. Virtue ethics‏‎ (3 revisions)
  89. Fractionation‏‎ (3 revisions)
  90. Isomers‏‎ (3 revisions)
  91. Voxel phantom‏‎ (3 revisions)
  92. Active (red) bone marrow‏‎ (3 revisions)
  93. Granulocyte-macrophage colony-stimulating factor‏‎ (3 revisions)
  94. Radiological Protection in Healthcare‏‎ (3 revisions - redirect page)
  95. Coster-Kronig transition‏‎ (3 revisions)
  96. Organ dose equivalent‏‎ (3 revisions)
  97. Granulocyte colony-stimulating factor‏‎ (3 revisions)
  98. Emergency preparedness‏‎ (3 revisions)
  99. Gray‏‎ (3 revisions)
  100. Spread-out Bragg peak‏‎ (3 revisions)
  101. Emergency procedures‏‎ (3 revisions)
  102. Absolute risk‏‎ (3 revisions)
  103. Auger transition‏‎ (3 revisions)
  104. Recovery‏‎ (3 revisions)
  105. Bystander effect‏‎ (3 revisions)
  106. Complex tissues‏‎ (3 revisions)
  107. Derived air concentration‏‎ (3 revisions)
  108. Dignity‏‎ (3 revisions)
  109. Wisdom‏‎ (3 revisions)
  110. Employer‏‎ (3 revisions)
  111. Activity median thermodynamic diameter‏‎ (3 revisions)
  112. Reversibility‏‎ (2 revisions)
  113. Clonogenic cells‏‎ (2 revisions)
  114. In vivo radiobioassay‏‎ (2 revisions)
  115. Solar particle event‏‎ (2 revisions)
  116. Curie‏‎ (2 revisions)
  117. Effect Dose 50‏‎ (2 revisions)
  118. Worker‏‎ (2 revisions)
  119. Nuclear track detectors‏‎ (2 revisions)
  120. Endogeneous excretion‏‎ (2 revisions)
  121. Exposure to Radon at Home‏‎ (2 revisions)
  122. GATA binding protein 2‏‎ (2 revisions)
  123. Radiation safety officer‏‎ (2 revisions)
  124. Radioresponsiveness‏‎ (2 revisions)
  125. Hormones‏‎ (2 revisions)
  126. Authorization‏‎ (2 revisions)
  127. Recovery responder‏‎ (2 revisions)
  128. Cardiac arrhythmias‏‎ (2 revisions)
  129. Right to know‏‎ (2 revisions)
  130. Clonogenic survival‏‎ (2 revisions)
  131. Incidence‏‎ (2 revisions)
  132. Solar wind‏‎ (2 revisions)
  133. Cytokines‏‎ (2 revisions)
  134. Target tissue‏‎ (2 revisions)
  135. Measuring and Reducing Radon Levels in your Home‏‎ (2 revisions)
  136. Working level‏‎ (2 revisions)
  137. OLINDA/EXM‏‎ (2 revisions)
  138. Particle radiance‏‎ (2 revisions)
  139. Protection strategy‏‎ (2 revisions)
  140. Acute radiation syndrome‏‎ (2 revisions)
  141. Radiation source‏‎ (2 revisions)
  142. Radiosensitiser‏‎ (2 revisions)
  143. Hounsfield unit‏‎ (2 revisions)
  144. Authorized limit‏‎ (2 revisions)
  145. Rehabilitation of living conditions‏‎ (2 revisions)
  146. ICRP Publication 118‏‎ (2 revisions)
  147. Cardiac valve diseases‏‎ (2 revisions)
  148. Rigidity‏‎ (2 revisions)
  149. Security‏‎ (2 revisions)
  150. Incident‏‎ (2 revisions)
  151. Intermediate level waste‏‎ (2 revisions)
  152. Stenosis‏‎ (2 revisions)
  153. Local DRL‏‎ (2 revisions)
  154. Disposal‏‎ (2 revisions)
  155. Tolerability‏‎ (2 revisions)
  156. Medical exposure‏‎ (2 revisions)
  157. Dose criteria‏‎ (2 revisions)
  158. Naturally occurring radioactive material‏‎ (2 revisions)
  159. Working level month‏‎ (2 revisions)
  160. Environmental exposure‏‎ (2 revisions)
  161. Exempt waste‏‎ (2 revisions)
  162. Adaptive response‏‎ (2 revisions)
  163. Alveolar-interstitial region‏‎ (2 revisions)
  164. Radiosensitivity, cellular‏‎ (2 revisions)
  165. Autoimmune disease‏‎ (2 revisions)
  166. Co-expertise‏‎ (2 revisions)
  167. Inclusiveness‏‎ (2 revisions)
  168. Connective tissue‏‎ (2 revisions)
  169. Source-related‏‎ (2 revisions)
  170. Internal conversion electron‏‎ (2 revisions)
  171. DRL process‏‎ (2 revisions)
  172. LD 50/30‏‎ (2 revisions)
  173. Telangiectasia‏‎ (2 revisions)
  174. Member of the public‏‎ (2 revisions)
  175. Unattached fraction‏‎ (2 revisions)
  176. Necrosis‏‎ (2 revisions)
  177. Environmental radiation protection‏‎ (2 revisions)
  178. Patient entrance reference point‏‎ (2 revisions)
  179. Exemption level‏‎ (2 revisions)
  180. Potential recoverability correction factor‏‎ (2 revisions)
  181. Protective action guide‏‎ (2 revisions)
  182. Radiation worker‏‎ (2 revisions)
  183. Cardioverter-defibrillator‏‎ (2 revisions)
  184. Self-help protection‏‎ (2 revisions)
  185. Individual-related‏‎ (2 revisions)
  186. Consequential late effects‏‎ (2 revisions)
  187. Storage‏‎ (2 revisions)
  188. Track structure‏‎ (2 revisions)
  189. Mendelian diseases‏‎ (2 revisions)
  190. Neurological syndrome‏‎ (2 revisions)
  191. Effective dose equivalent‏‎ (2 revisions)
  192. Occupational exposure‏‎ (2 revisions)
  193. Peak skin dose‏‎ (2 revisions)
  194. Existing exposure situation‏‎ (2 revisions)
  195. Gastroschisis‏‎ (2 revisions)
  196. Radioactive dispersion device‏‎ (2 revisions)
  197. Angiogenesis‏‎ (2 revisions)
  198. Radon: Units of Measure‏‎ (2 revisions)
  199. Hyperbaric oxygen‏‎ (2 revisions)
  200. Reference air kerma‏‎ (2 revisions)
  201. Bioturbation‏‎ (2 revisions)
  202. ICRP Task Groups on Radiological Protection in Healthcare‏‎ (2 revisions)
  203. Cohort study‏‎ (2 revisions)
  204. Individual decontamination‏‎ (2 revisions)
  205. DRL value‏‎ (2 revisions)
  206. Subcutaneous tissue‏‎ (2 revisions)
  207. Low dose rate‏‎ (2 revisions)
  208. Transfer compartment‏‎ (2 revisions)
  209. Mitigation‏‎ (2 revisions)
  210. Upper reference levels‏‎ (2 revisions)
  211. Neurovascular syndrome‏‎ (2 revisions)
  212. Epithelium‏‎ (2 revisions)
  213. Pelagic‏‎ (2 revisions)
  214. Practical radiological protection culture‏‎ (2 revisions)
  215. Acceptance test‏‎ (2 revisions)
  216. Gastrulation‏‎ (2 revisions)
  217. Radioactive source‏‎ (2 revisions)
  218. Habitual mouth breather‏‎ (2 revisions)
  219. Annihilation photons‏‎ (2 revisions)
  220. Hyperfractionation‏‎ (2 revisions)
  221. Bone marrow‏‎ (2 revisions)
  222. Risk coefficient‏‎ (2 revisions)
  223. Individual monitoring‏‎ (2 revisions)
  224. Containment‏‎ (2 revisions)
  225. Source term‏‎ (2 revisions)
  226. Latent time/period or latency interval‏‎ (2 revisions)
  227. Low level waste‏‎ (2 revisions)
  228. Dose-length product‏‎ (2 revisions)
  229. Equieffective dose‏‎ (2 revisions)
  230. Expanded and aligned radiation field‏‎ (2 revisions)
  231. Qualified expert‏‎ (2 revisions)
  232. Adventitious‏‎ (2 revisions)
  233. Radioactive substance‏‎ (2 revisions)
  234. Habitual nose breather‏‎ (2 revisions)
  235. Hypertrophic cardiomyopathy‏‎ (2 revisions)
  236. Background dose (rate)‏‎ (2 revisions)
  237. Reference biokinetic model‏‎ (2 revisions)
  238. Relocation‏‎ (2 revisions)
  239. ICRPædia Guide to Dose Coefficients‏‎ (2 revisions)
  240. Intervention Level‏‎ (2 revisions)
  241. Substantial radiation dose level‏‎ (2 revisions)
  242. Detriment‏‎ (2 revisions)
  243. Dose-rate effect‏‎ (2 revisions)
  244. Transfer rate‏‎ (2 revisions)
  245. Multi-detector computed tomography‏‎ (2 revisions)
  246. Electron-capture decay‏‎ (2 revisions)
  247. Percutaneous coronary intervention‏‎ (2 revisions)
  248. Prevailing circumstances‏‎ (2 revisions)
  249. Fluoroscopically or computed tomography guided interventions‏‎ (2 revisions)
  250. Radon Recommendations for Authorities‏‎ (2 revisions)
  251. Hypoplasia‏‎ (2 revisions)
  252. Backscatter detection system‏‎ (2 revisions)
  253. Reference individual‏‎ (2 revisions)
  254. Bradycardia‏‎ (2 revisions)
  255. Remedial action‏‎ (2 revisions)
  256. Risk of Exposure to Radon‏‎ (2 revisions)
  257. Coronary heart disease‏‎ (2 revisions)
  258. South Atlantic anomaly‏‎ (2 revisions)
  259. Interventional procedure‏‎ (2 revisions)
  260. Decay constant‏‎ (2 revisions)
  261. Lymphatic system‏‎ (2 revisions)
  262. Transforming growth factor‏‎ (2 revisions)
  263. Dose of record Hp (10)‏‎ (2 revisions)
  264. Electrophysiology‏‎ (2 revisions)
  265. Pericarditis‏‎ (2 revisions)
  266. Principle of application of dose limits‏‎ (2 revisions)
  267. Accreditation‏‎ (2 revisions)
  268. Genomic integrity‏‎ (2 revisions)
  269. Radioactivity‏‎ (2 revisions)
  270. Hazard‏‎ (2 revisions)
  271. Radon Recommendations for Workplaces‏‎ (2 revisions)
  272. Reference level‏‎ (2 revisions)
  273. Bragg peak‏‎ (2 revisions)
  274. Remediation‏‎ (2 revisions)
  275. Chronic exposure‏‎ (2 revisions)
  276. Routine monitoring‏‎ (2 revisions)
  277. ICRPædia Guide to Radon‏‎ (2 revisions)
  278. Colony‏‎ (2 revisions)
  279. Cosmic Radiation in Aviation‏‎ (2 revisions)
  280. Special (non-routine) monitoring‏‎ (2 revisions)
  281. Decommissioning‏‎ (2 revisions)
  282. Lifetime risk‏‎ (2 revisions)
  283. Macrophage colony stimulating factor‏‎ (2 revisions)
  284. Dose-threshold‏‎ (2 revisions)
  285. Multiplicative risk projection model‏‎ (2 revisions)
  286. Fractional absorption in the gastrointestinal tract‏‎ (2 revisions)
  287. Action Level‏‎ (2 revisions)
  288. Health Surveillance‏‎ (2 revisions)
  289. Basal cell‏‎ (2 revisions)
  290. Branching fraction‏‎ (2 revisions)
  291. Repopulation‏‎ (2 revisions)
  292. Class SR-0 gases‏‎ (2 revisions)
  293. ICRPædia Guide to the Basics of Ionising Radiation‏‎ (2 revisions)
  294. Decontamination‏‎ (2 revisions)
  295. Diastasis‏‎ (2 revisions)
  296. Threshold dose for tissue reactions‏‎ (2 revisions)
  297. Magnetosphere‏‎ (2 revisions)
  298. Dose per unit intake coefficient‏‎ (2 revisions)
  299. Emergency‏‎ (2 revisions)
  300. Exposure, external or internal‏‎ (2 revisions)
  301. Graft vs host disease‏‎ (2 revisions)
  302. Air-kerma, incident‏‎ (2 revisions)
  303. Radiographer‏‎ (2 revisions)
  304. Heliosphere‏‎ (2 revisions)
  305. Representative organism (non-human biota)‏‎ (2 revisions)
  306. Class SR-1 gases‏‎ (2 revisions)
  307. Safety‏‎ (2 revisions)
  308. Committed effective dose‏‎ (2 revisions)
  309. Cost-benefit analysis‏‎ (2 revisions)
  310. Specific effective energy‏‎ (2 revisions)
  311. Decontamination factor‏‎ (2 revisions)
  312. Limitation of dose‏‎ (2 revisions)
  313. Transmission detection system‏‎ (2 revisions)
  314. Multistage tumorigenesis‏‎ (2 revisions)
  315. Dose rate‏‎ (2 revisions)
  316. Non-sphericity parameter‏‎ (2 revisions)
  317. Emergency exposure situation‏‎ (2 revisions)
  318. Erythropoietin‏‎ (2 revisions)
  319. Pharynx‏‎ (2 revisions)
  320. Exposure (in the context of inhalation)‏‎ (2 revisions)
  321. Fractionation and dose delivery patterns‏‎ (2 revisions)
  322. Broad beam therapy irradiation technique‏‎ (2 revisions)
  323. Representative person‏‎ (2 revisions)
  324. Class SR-2 gases‏‎ (2 revisions)
  325. Safety case‏‎ (2 revisions)
  326. Committed equivalent dose‏‎ (2 revisions)
  327. Slow repair‏‎ (2 revisions)
  328. Isotropic geometry‏‎ (2 revisions)
  329. Lineal energy‏‎ (2 revisions)
  330. Dichotomous‏‎ (2 revisions)
  331. Thyroid blocking‏‎ (2 revisions)
  332. Transparency‏‎ (2 revisions)
  333. Dose rate effectiveness factor‏‎ (2 revisions)
  334. Waste disposal‏‎ (2 revisions)
  335. Non-targeted effects‏‎ (2 revisions)
  336. Emergency plan‏‎ (2 revisions)
  337. Ethics‏‎ (2 revisions)
  338. ALARA‏‎ (2 revisions)
  339. Procedural values‏‎ (2 revisions)
  340. Hierarchical tissues‏‎ (2 revisions)
  341. Area monitoring‏‎ (2 revisions)
  342. Benthic‏‎ (2 revisions)
  343. Bronchial region‏‎ (2 revisions)
  344. Reproductive integrity‏‎ (2 revisions)
  345. Clearance‏‎ (2 revisions)
  346. Safety culture‏‎ (2 revisions)
  347. Solar cosmic radiation‏‎ (2 revisions)
  348. Inhalability‏‎ (2 revisions)
  349. Spontaneous fission‏‎ (2 revisions)
  350. Itinerant (radiation) worker‏‎ (2 revisions)
  351. Deontological Ethics‏‎ (2 revisions)
  352. Linear-non-threshold model‏‎ (2 revisions)
  353. Differentiation‏‎ (2 revisions)
  354. Trapped particles‏‎ (2 revisions)
  355. Orphan source‏‎ (2 revisions)
  356. Planned exposure situation‏‎ (2 revisions)
  357. Progenitor cell‏‎ (2 revisions)
  358. Activity‏‎ (2 revisions)
  359. Radiation belt‏‎ (2 revisions - redirect page)
  360. High level waste‏‎ (2 revisions)
  361. Reasonableness‏‎ (2 revisions)
  362. Residual dose‏‎ (2 revisions)
  363. Respiratory protection‏‎ (2 revisions)
  364. Clearance level‏‎ (2 revisions)
  365. Scintigraphy‏‎ (2 revisions)
  366. Solar cycle‏‎ (2 revisions)
  367. Inner bremsstrahlung‏‎ (2 revisions)
  368. Systemic model‏‎ (2 revisions)
  369. Linear-quadratic dose response model‏‎ (2 revisions)
  370. Time factor‏‎ (2 revisions)
  371. Dose constraint‏‎ (2 revisions)
  372. Myocardial perfusion‏‎ (2 revisions)
  373. Early normal tissue responses‏‎ (2 revisions)
  374. What is Radon?‏‎ (2 revisions)
  375. Platelet-derived growth factor‏‎ (2 revisions)
  376. Radiation modifier‏‎ (2 revisions)
  377. Radiological protection principles‏‎ (2 revisions)
  378. Beta-minus decay‏‎ (2 revisions)
  379. Retrievability‏‎ (2 revisions)
  380. Immune system‏‎ (2 revisions)
  381. Institutional control‏‎ (2 revisions)
  382. Cumulative dose‏‎ (2 revisions)
  383. Stakeholder‏‎ (2 revisions)
  384. Tachycardia‏‎ (2 revisions)
  385. Tissue equivalent material‏‎ (2 revisions)
  386. Dose conversion coefficient‏‎ (2 revisions)
  387. Myocardial stress test‏‎ (2 revisions)
  388. Edema‏‎ (2 revisions)
  389. Oversight‏‎ (2 revisions)
  390. Excess relative risk‏‎ (2 revisions)
  391. Exposure situation‏‎ (2 revisions)
  392. Projected dose‏‎ (2 revisions)
  393. Growth factor‏‎ (2 revisions)
  394. Alimentary tract transfer factor‏‎ (2 revisions)
  395. Radionuclides of natural origin‏‎ (2 revisions)
  396. Recovery (cellular or tissue)‏‎ (2 revisions)
  397. Beta-plus decay‏‎ (2 revisions)
  398. Calculating Doses from Intakes of Radionuclides‏‎ (2 revisions)
  399. ICRP Publication 96‏‎ (1 revision)
  400. ICRP Publication 130‏‎ (1 revision)
  401. Secondary radiation‏‎ (1 revision)
  402. ICRP Publication 145‏‎ (1 revision)
  403. Intake‏‎ (1 revision)
  404. ICRP Publication 2‏‎ (1 revision)
  405. Standard-size adult‏‎ (1 revision)
  406. ICRP Publication 30 (Part 3)‏‎ (1 revision)
  407. Derived consideration reference level‏‎ (1 revision)
  408. ICRP Publication 40‏‎ (1 revision)
  409. Tissue reaction‏‎ (1 revision)
  410. Measured quantity‏‎ (1 revision)
  411. ICRP Publication 55‏‎ (1 revision)
  412. Dose conversion convention‏‎ (1 revision)
  413. Tumour suppressor gene‏‎ (1 revision)
  414. National DRL‏‎ (1 revision)
  415. ICRP Publication 7‏‎ (1 revision)
  416. ICRP Publication 84‏‎ (1 revision)
  417. Oxygen enhancement ratio‏‎ (1 revision)
  418. Exclusion‏‎ (1 revision)
  419. Population risk‏‎ (1 revision)
  420. Acute exposure‏‎ (1 revision)
  421. Allometry‏‎ (1 revision)
  422. ICRP Publication 102‏‎ (1 revision)
  423. Registry‏‎ (1 revision)
  424. ICRP Publication 116‏‎ (1 revision)
  425. ICRP Publication 97‏‎ (1 revision)
  426. ICRP Publication 131‏‎ (1 revision)
  427. Secretory cells‏‎ (1 revision)
  428. ICRP Publication 146‏‎ (1 revision)
  429. Concentration ratio‏‎ (1 revision)
  430. Intensity-modulated radiotherapy‏‎ (1 revision)
  431. ICRP Publication 20‏‎ (1 revision)
  432. Stem cell‏‎ (1 revision)
  433. Kerma approximation‏‎ (1 revision)
  434. ICRP Publication 30 (Part 4)‏‎ (1 revision)
  435. Derived investigation level‏‎ (1 revision)
  436. ICRP Publication 41‏‎ (1 revision)
  437. Directional dose equivalent‏‎ (1 revision)
  438. ICRP Publication 56‏‎ (1 revision)
  439. Dose conversion factor‏‎ (1 revision)
  440. National radon survey‏‎ (1 revision)
  441. ICRP Publication 70‏‎ (1 revision)
  442. Effect modifier‏‎ (1 revision)
  443. ICRP Publication 85‏‎ (1 revision)
  444. Endosteum‏‎ (1 revision)
  445. Potential alpha energy concentration‏‎ (1 revision)
  446. Redox‏‎ (1 revision)
  447. Biological half-life‏‎ (1 revision)
  448. ICRP Publication 117‏‎ (1 revision)
  449. ICRP Publication 98‏‎ (1 revision)
  450. ICRP Publication 132‏‎ (1 revision)
  451. Clonogenic surviving fraction‏‎ (1 revision)
  452. ICRP Publication 147‏‎ (1 revision)
  453. Cone beam computed tomography‏‎ (1 revision)
  454. Somatic effect‏‎ (1 revision)
  455. ICRP Publication 21‏‎ (1 revision)
  456. ICRP Publication 30 (Supplement A to Part 3)‏‎ (1 revision)
  457. Derived limit‏‎ (1 revision)
  458. Targeted effects‏‎ (1 revision)
  459. ICRP Publication 42‏‎ (1 revision)
  460. ICRP Publication 57‏‎ (1 revision)
  461. Typical value‏‎ (1 revision)
  462. ICRP Publication 71‏‎ (1 revision)
  463. ICRP Publication 86‏‎ (1 revision)
  464. Particle transport‏‎ (1 revision)
  465. Human Alimentary Tract Model‏‎ (1 revision)
  466. ICRP Publication 104‏‎ (1 revision)
  467. Biomarker‏‎ (1 revision)
  468. Relative biological effectiveness‏‎ (1 revision)
  469. ICRP Publication 119‏‎ (1 revision)
  470. ICRP Publication 99‏‎ (1 revision)
  471. ICRP Publication 133‏‎ (1 revision)
  472. Security screening‏‎ (1 revision)
  473. ICRP Publication 148‏‎ (1 revision)
  474. ICRP Publication 22‏‎ (1 revision)
  475. Stochastic effect‏‎ (1 revision)
  476. ICRP Publication 30 (Supplement B to Part 3)‏‎ (1 revision)
  477. Derived reference level‏‎ (1 revision)
  478. ICRP Publication 43‏‎ (1 revision)
  479. Disposal facility‏‎ (1 revision)
  480. Tolerance dose‏‎ (1 revision)
  481. ICRP Publication 58‏‎ (1 revision)
  482. ICRP Publication 72‏‎ (1 revision)
  483. Occupancy factor‏‎ (1 revision)
  484. ICRP Publication 87‏‎ (1 revision)
  485. Absorption Type‏‎ (1 revision - redirect page)
  486. Additional dose‏‎ (1 revision)
  487. Ambient dose equivalent‏‎ (1 revision)
  488. Radon-prone area‏‎ (1 revision)
  489. Human Respiratory Tract Model‏‎ (1 revision)
  490. Automatic exposure control‏‎ (1 revision)
  491. Reference Person‏‎ (1 revision)
  492. ICRP Publication 105‏‎ (1 revision)
  493. Relative life lost‏‎ (1 revision)
  494. ICRP Publication 12‏‎ (1 revision)
  495. Ring chromosome‏‎ (1 revision)
  496. ICRP Supporting Guidance 2‏‎ (1 revision)
  497. ICRP Publication 134‏‎ (1 revision)
  498. Cobblestone area forming cell assay‏‎ (1 revision)
  499. ICRP Publication 149‏‎ (1 revision)
  500. International Commission on Radiological Protection‏‎ (1 revision)

View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://icrpaedia.org/Special:MostRevisions"